HOME / CONTACT US
繁體版 / 简体版
 

Drug License


  • MS-20 is a mixture of soybean fermentation metabolites which is produced in strictly controlled fermenter and with carefully chosen microorganisms that mimics the human intestinal environment.

  • The manufacturing and R&D procedures of Chemo young follow the international regulations.MS-20 was approved as the new drug by MOHW in 2011.

  • MS-20 can promote the growth of probiotics and act as an immunomodulator to improve immunity and inhibit tumor growth.

  • MS-20 is the first and the only oral new drug for ameliorating fatigue and appetite loss in patients receiving chemotherapy and thus improves the quality of life.

  • MS-20 is estimated to be approximately NT$4.5 billion in the Taiwan market, with an annual increase of 90,000 cancer patients. The number of cancer patients worldwide will reach 1.4 million, and medical needs will exceed $20 billion annually.

  • Herbiron in accordance with the concept of Chinese and Western cultures, is composed of Chinese herbal medicine and well-known study Ferrous Bisglycinate.

  • Ferrous Bisglycinate is easily absorbed by the body, can increase iron utilization, more than other iron supplements.

  • Herbiron was approved as the new drug by Ministry of Health and Welfare (MOHW) in 2013.

  • Herbiron's clinical efficacy was confirmed in Phase III trials to significantly improve symptoms of iron deficiency anemia in women before menopause and relieved Dysmenorrhea.

  • The safety of Herbiron was demonstrated in Phase III trials, and the incidence of gastrointestinal side effects was significantly reduced in Herbiron-treated subjects compared to subjects treated with ferrous sulfate.